Cargando…

Medicinal chemistry of anticancer drugs /

Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and b...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Avenda�no, Carmen
Otros Autores: Men�endez, J. Carlos (Jos�e Carlos)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam : Elsevier Science, 2015.
Edición:2nd ed.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 a 4500
001 SCIDIR_ocn911246573
003 OCoLC
005 20231120112005.0
006 m o d
007 cr cnu---unuuu
008 150620s2015 ne o 001 0 eng d
040 |a EBLCP  |b eng  |e pn  |c EBLCP  |d OPELS  |d E7B  |d UIU  |d UV0  |d OCLCF  |d OCLCQ  |d BUF  |d OCLCO  |d MERER  |d OCLCO  |d OCLCQ  |d U3W  |d OCLCO  |d D6H  |d UKMGB  |d WYU  |d OCLCO  |d OCLCA  |d OCLCQ  |d S2H  |d OCLCO  |d OCLCQ  |d OCLCO 
015 |a GBB6G6316  |2 bnb 
016 7 |a 018086898  |2 Uk 
020 |z 9780444626493 
020 |z 0444626492 
020 |z 9780444626677 
020 |z 0444626670 
035 |a (OCoLC)911246573 
050 4 |a RC271.C5 
082 0 4 |a 616.994061 
100 1 |a Avenda�no, Carmen. 
245 1 0 |a Medicinal chemistry of anticancer drugs /  |c by Carmen Avenda�no and J. Carlos Men�endez. 
250 |a 2nd ed. 
260 |a Amsterdam :  |b Elsevier Science,  |c 2015. 
300 |a 1 online resource (767 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 0 |a Print version record. 
500 |a Includes index. 
520 |a Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. 
505 0 |a Front Cover; Medicinal Chemistry of Anticancer Drugs; Copyright; Contents; Foreword; Preface; Abbreviations; Chapter 1: General Aspects of Cancer Chemotherapy; 1. Introduction: Some General Comments About Cancer; 2. Tumorigenesis and Oncogenes: Pharmacogenomics; 3. Early Diagnosis of Cancer and Its Therapeutic Relevance; 4. A Brief History of Cancer Chemotherapy; 5. General Comments About Anticancer Drug Discovery; 6. Combination Therapy and Personalized Anticancer Treatments; 7. Natural Products in Cancer Chemotherapy; 8. A Brief Comment About Cancer Nanotechnology. 
505 8 |a 9. Summary of FDA-Approved Anticancer DrugsReferences; Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis; 1. Introduction; 2. Inhibitors of the Biosynthesis of Uridylic Acid; 3. Inhibitors of Ribonucleotide Reductase; 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase; 3.2. Gallium Salts and Complexes; 3.3. Radical Scavengers; 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors; 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase; 4. Inhibitors of the Biosynthesis of Thymidilic Acid. 
505 8 |a 4.1. Thymidylate Synthase4.2. 5-Fluorouracil and Floxuridine; 4.3. 5-Fluorouracil Prodrugs; 4.4. Modulation of 5-Fluorouracil Activity; 4.4.1. Decreased Degradation of 5-FU; 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU; 4.4.3. Enhancement of 5-FU Activation; 4.5. Trifluridine; 4.6. Folate-Based Thymidylate Synthase Inhibitors; 5. Inhibitors of Dihydrofolate Reductase; 5.1. Classical DHFR Inhibitors; 5.2. Nonclassical (Lipophilic) DHFR Inhibitors; 6. Inhibitors of the De Novo Purine Biosynthesis Pathway; 6.1. Inhibitors of PRPP Amidotransferase. 
505 8 |a 6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase; 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase; 6.5. Thiopurines and Related Compounds; 7. Inhibitors of Adenosine Deaminase; 8. Inhibitors of Late Stages in DNA Synthesis; 8.1. Pyrimidine Nucleosides; 8.2. Purine Nucleosides; 9. Antimetabolite Enzymes; References; Chapter 3: Anticancer Drugs That Modulate Hormone Action; 1. Introduction; 2. Estrogens and Their Involvement in Carcinogenesis; 3. Antiestrogens as Antitumor Drugs. 
505 8 |a 3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators)3.2. Steroidal Antiestrogens; 4. Aromatase Inhibitors; 4.1. Aromatase Mechanism of Action; 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors); 4.3. C-19 Modified Substrate Analogs; 4.4. 4-Hydroxyandrostenedione Derivatives; 4.5. Steroids with Additional Unsaturations at the A and B Rings; 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors; 4.7. Nonsteroidal Aromatase Inhibitors (Type II); 5. Steroid Sulfatase Inhibitors; 6. Androgen-Related Antitumor Agents; 6.1. Antiandrogens. 
650 0 |a Cancer  |x Chemotherapy. 
650 0 |a Drugs  |x Design. 
650 0 |a Pharmaceutical chemistry. 
650 2 |a Neoplasms  |x therapy  |0 (DNLM)D009369Q000628 
650 2 |a Drug Design  |0 (DNLM)D015195 
650 2 |a Chemistry, Pharmaceutical  |0 (DNLM)D002626 
650 6 |a Cancer  |x Chimioth�erapie.  |0 (CaQQLa)201-0004691 
650 6 |a M�edicaments  |x Conception.  |0 (CaQQLa)201-0203461 
650 6 |a Chimie pharmaceutique.  |0 (CaQQLa)201-0028674 
650 7 |a Cancer  |x Chemotherapy  |2 fast  |0 (OCoLC)fst00845327 
650 7 |a Drugs  |x Design  |2 fast  |0 (OCoLC)fst00898790 
650 7 |a Pharmaceutical chemistry  |2 fast  |0 (OCoLC)fst01060115 
700 1 |a Men�endez, J. Carlos  |q (Jos�e Carlos) 
776 0 8 |i Print version:  |a Avendano, Carmen.  |t Medicinal Chemistry of Anticancer Drugs.  |d Burlington : Elsevier Science, �2015  |z 9780444626493 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/book/9780444626493  |z Texto completo